Lupin Receives FDA Approval for Dapagliflozin and Metformin Hydrochloride Tablets

Lupin Limited Gains FDA Approval for Innovative Diabetes Treatment

On April 8, 2026, Lupin Limited, a leading global pharmaceutical company headquartered in Mumbai, announced a significant milestone in its journey of innovation and commitment to health. The company received approval from the United States Food and Drug Administration (FDA) for its Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets.

Details of the Approval

The FDA sanctioned various dosages of this medication, namely 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg variants for the treatment of type 2 diabetes. Additionally, Lupin also secured tentative approval for the 2.5 mg/1,000 mg dosage. This approval underscores the company's capacity to meet patient needs with effective and accessible therapeutic options.

Lupin's Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets are recognized as bioequivalent to Xigduo® XR, a product owned by AstraZeneca, reinforcing Lupin’s role in delivering high-quality generics in the market. The FDA's endorsement reflects rigorous reviews of the company's application and aligns with its commitment to patient safety and efficacy.

Lupin's Commitment to Health Innovations

Lupin Limited stands as a prominent entity in the pharmaceutical realm, with its products available across more than 100 global markets. The company specializes in a wide range of pharmaceutical offerings, from generic formulations to complex biologics and active pharmaceutical ingredients. Recently, Lupin has been focusing on therapeutic areas that include respiratory health, cardiovascular conditions, diabetes care, and women's health issues, among others.

With 15 state-of-the-art manufacturing sites and 7 dedicated research centers, the company employs over 24,000 individuals worldwide, all working towards enhancing health outcomes for patients. Their recent approval signifies both a major achievement for the company and a step forward in the ongoing battle against diabetes in the United States.

Future Aspiration

Lupin Limited made its mark by striving to improve healthcare access through affordability and innovation. By expanding their portfolio with these FDA-approved medications, they aim to reach even more patients who require effective diabetes management solutions. Their endeavors through subsidiaries such as Lupin Diagnostics and Lupin Digital Health are further testament to their holistic approach to health.

Moving forward, Lupin Limited remains committed to developing new therapies and increasing its footprint in the global pharmaceutical landscape. The approval of Dapagliflozin and Metformin Hydrochloride is not just an achievement for Lupin but a beacon of hope for many living with diabetes, illustrating the importance of collaboration between pharmaceutical companies and regulatory bodies to improve global health outcomes.

To learn more about Lupin Limited and its innovative pharmaceutical solutions, visit www.lupin.com or connect with them on LinkedIn.